Gavilyte - C Powder, For Solution
NDC Package 43386-060-19
Package Information
Gavilyte - C (polyethylene glycol-3350 and electrolytes with flavor pack) powders is gaviLyte- C with flavor pack is indicated for bowel cleansing prior to colonoscopy or barium enema X-ray examination. This formulation utilizes a powder, for solution delivery system. Marketed by Lupin Pharmaceuticals,inc., this product is identified by NDC 43386-060 and is authorized under FDA application ANDA090186.
Identification & Billing
- RxCUI: 966914 - polyethylene glycol 3350 240 GM / potassium chloride 2.98 GM / sodium bicarbonate 6.74 GM / sodium chloride 5.86 GM / sodium sulfate 227.41 GM Powder for Oral Solution
- RxCUI: 966914 - polyethylene glycol 3350 240000 MG / potassium chloride 2980 MG / sodium bicarbonate 6720 MG / sodium chloride 5840 MG / sodium sulfate 22720 MG Powder for Oral Solution
- RxCUI: 966914 - POLYETHYLENE GLYCOL 3350 240000 MG / K+ Chloride 2980 MG / NaHCO3 6720 MG / NaCl 5840 MG / sodium sulfate 22720 MG Powder for Oral Solution
- RxCUI: 966914 - POLYETHYLENE GLYCOL 3350 240000 MG / Pot Chloride 2980 MG / NaHCO3 6720 MG / NaCl 5840 MG / sodium sulfate 22720 MG Powder for Oral Solution
- RxCUI: 967023 - Gavilyte-C Powder for Oral Solution
Clinical Specifications
- Increased Large Intestinal Motility - [PE] (Physiologic Effect)
- Increased Large Intestinal Motility - [PE] (Physiologic Effect)
- Inhibition Large Intestine Fluid/Electrolyte Absorption - [PE] (Physiologic Effect)
- Osmotic Activity - [MoA] (Mechanism of Action)
- Osmotic Laxative - [EPC] (Established Pharmacologic Class)
- Potassium Compounds - [CS]
- Potassium Salt - [EPC] (Established Pharmacologic Class)
- Stimulation Large Intestine Fluid/Electrolyte Secretion - [PE] (Physiologic Effect)
Regulatory & Marketing
Hierarchy Structure
- 43386 - Lupin Pharmaceuticals,inc.
- 43386-060 - Gavilyte - C
- 43386-060-19 - 278.26 g in 1 BOTTLE
- 43386-060 - Gavilyte - C
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 43386-060-19 identifies a specific commercial package of 278.26 g in 1 bottle of Gavilyte - C TM, a human prescription drug labeled by Lupin Pharmaceuticals,inc.. This powder, for solution is formulated for oral use and contains polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride; sodium sulfate anhydrous as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Lupin Pharmaceuticals,inc. on January 06, 2009. The current certification is valid through December 31, 2026.
How is this Lupin Pharmaceuticals,inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 43386006019. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.